Mallinckrodt Announces Enrollment of First Patient in Phase 1/2a StrataSOMA Clinical Trial of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) for Investigating the Treatment of Full-Thickness Burns
- Thursday, December 16, 2021, 7:04
- Finance
- Add a comment
DUBLIN, Dec. 16, 2021 /PRNewswire/ — Mallinckrodt plc (OTCMKTS:MNKKQ), a global biopharmaceutical company, today announced enrollment of the first patient in StrataSOMA, a Phase 1/2a clinical trial that is assessing StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts…
About the Author
adminasapcorp has written 42014 stories on this site.